Skip to main content
SIU School of Medicine Logo

Domain Menu

  • Patient Care
  • School of Medicine

Main Menu Edu Secondary

  • faculty
  • intranet
  • library
  • news & events
  • donate
  • careers
I am a...
  • Patient
  • Donor or Friend
  • Prospective Employee
  • Student/Prospective Student
  • Resident or Fellow
  • Alumni

Main Menu Edu

Main Menu Close
Main Menu
  • Degree Programs
  • Research
  • Academic & Clinical Departments
  • Centers & Institutes
  • Community Programs
    • Equity, Diversity and Inclusion
    • External Relations
    • Family and Community Medicine
    • Office of Community Health Work
    • Office of Correctional Medicine
    • Population Science and Policy
    • Rural Health and Social Service Development
  • About Us
    • Administrative offices
    • Careers
    • Why SIU School of Medicine
      • Strategic plan
      • A Model for Medical Education
      • Facts and figures
      • Our campuses
    • Economic Impact Report (pdf)
    • History
      • Notable alumni
      • Points of pride
      • Timeline
    • Leadership
      • SIU Medicine Board of Directors
      • SIU School of Medicine Leadership
    • News and Events

Group Menu

Main Menu Close Main Menu Close
Main Menu
  • Simmons Cancer Institute
  • About Us
    • Welcome to Simmons Cancer Institute
    • Doctors
    • Faculty
    • SCI pharmacy
  • Programs
    • Side-by-Side Wellness
    • Support groups
    • Wig Salon
  • Events
    • Annual Butterfly Release
    • Denim & Diamonds
    • Women's Power Lunch
  • Clinical care
  • Education
    • Hematology / Oncology Fellowship
    • SCI Summer Internship
  • Research
    • Clinical trials
    • Join the team
    • Team Science Grants (TSGs)
  • Find Us
Search Site close Close

Breadcrumb

  1. Home
  2. ASND0029 "IL Believe": A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in

This study is investigating experimental drugs TransCon IL-2 β/γ and TransCon TLR7/8 for the treatment of advanced/metastatic solid tumors (melanoma, breast cancer, cervical cancer, ovarian cancer) in adults.

Research
Patient
Simmons Cancer Institute
Active, recruiting
217-545-1946
Related Profiles
Krishna Rao
Kathy Robinson
sciresearchbc@siumed.edu
Kathy Robinson
https://clinicaltrials.gov/study/NCT05081609

This browser is no longer supported and some key features will not work. We strongly recommend using Edge, Chrome 70+, Safari 5.x+ and Firefox 5.x+.

SIU School of Medicine Logo
© 2025 SIU Board of Trustees all rights reserved

Legal

  • Equal Opportunity Employer
  • Nondiscrimination Statement
  • Privacy Policy
  • FOIA
  • ADA

About Us

  • About Us
  • Contact
  • SIU Intranet
  • SIU Medicine
  • Southern Illinois University Carbondale
  • Southern Illinois University Edwardsville
  • Southern Illinois University System

Social

  • Facebook
  • Twitter
  • Youtube
  • Instagram